SCHEMBL4408215

SCHEMBL4408215

CC(=O)N1CC2CC1CN2

nearest known ligand 0.62

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 9/20 0.62
CHRNA4 P43681 9/20 0.62
CHRNA3 P32297 7/20 0.62
CHRNB3 Q05901 2/20 0.62
CHRNA6 Q15825 2/20 0.62
KDM1A O60341 2/20 0.38
CHRNB4 P30926 5/20 0.37
CHRNA7 P36544 4/20 0.37
ATM Q13315 1/20 0.36
HSD11B1 P28845 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13050999 1.00 CHRNB2 (0.62) CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6
SCHEMBL1008896 1.00 CHRNB2 (0.62) CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6
Hydrochloric Acid SCHEMBL743237 0.98 CHRNB2 (0.61) CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6
Hydrochloric Acid SCHEMBL743238 0.98 CHRNB2 (0.61) CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6
Hydrochloric Acid SCHEMBL743978 0.98 CHRNB2 (0.61) CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6
SCHEMBL13761212 0.82 CHRNB2 (0.47) CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6
SCHEMBL12141565 0.82 CHRNB2 (0.47) CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6
SCHEMBL12356596 0.82 CHRNB2 (0.47) CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6
SCHEMBL335652 0.82 CHRNB2 (0.65) CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6
SCHEMBL12356559 0.82 CHRNB2 (0.65) CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116323623-A Pyrido [2,3-d ] pyrimidin-4-amines as SOS1 inhibitors 拜耳公司 2023-06-23 CN claimed
WO-2024108198-A2 METHODS OF TREATING OBESITY WITH AN MC4R AGONIST RHYTHM PHARMACEUTICALS, INC. (US) 2024-05-23 WO disclosed
CN-116323623-A Pyrido [2,3-d ] pyrimidin-4-amines as SOS1 inhibitors 拜耳公司 2023-06-23 CN disclosed
WO-2022109148-A1 SMALL MOLECULE INHIBITORS OF SARS-COV-2 INFECTIONS THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) 2022-05-27 WO disclosed
US-20190352313-A1 1H-PYRROLE-2,5-DIONE COMPOUNDS AND METHODS OF USING THEM TO INDUCE SELF-RENEWAL OF STEM/PROGENITOR SUPPORTING CELLS Frequency Therapeutics, Inc. 2019-11-21 US disclosed
EP-3527561-A1 NOVEL SUBSTITUTED PYRIMIDINE COMPOUNDS Grünenthal GmbH (DE) 2019-08-21 EP disclosed
EP-2997032-B1 6-BRIDGED HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION HOFFMANN LA ROCHE (CH) 2018-07-25 EP disclosed
US-20180148418-A1 AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-05-31 US disclosed
WO-2018078005-A1 AMIDO-SUBSTITUTED AZASPIRO DERIVATIVES AS TANKYRASE INHIBITORS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-05-03 WO disclosed
US-9758530-B2 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection HOFFMANN-LA ROCHE INC. (US) 2017-09-12 US disclosed
US-20090156465-A1 DERIVATIVES OF BETA-AMINO ACID AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2009-06-18 US disclosed
WO-2009063364-A2 MODULATORS OF UROTENSIN RECEPTOR AND METHODS OF USE THEREOF ENCYSIVE PHARMACEUTICALS INC. (US) 2009-05-22 WO disclosed
EP-1385506-B1 ACYLATED PIPERIDINE DERIVATES AS MELANOCORTIN-4 RECEPTOR AGONISTS MERCK & CO INC (US) 2009-05-06 EP disclosed
US-7504511-B2 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof SANOFI-AVENTIS (FR) 2009-03-17 US disclosed
EP-1411940-B1 BRIDGED PIPERIDINE DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS MERCK & CO INC (US) 2008-10-15 EP disclosed
EP-1973918-A2 DERIVATIVES OF BETA-AMINO ACID AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS RANBAXY LABORATORIES, LTD. (IN) 2008-10-01 EP disclosed
US-7414057-B2 Piperazine urea derivatives as melanocortin-4 receptor agonists MERCK & CO., INC. (US) 2008-08-19 US disclosed
US-7414057-B2 Piperazine urea derivatives as melanocortin-4 receptor agonists MERCK & CO., INC. (US) 2008-08-19 US disclosed
WO-2007077508-A2 DERIVATIVES OF BETA-AMINO ACID AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2007-07-12 WO disclosed
US-5707985-A Naphthyl-, quinolyl- and isoquinolyl- sulfonamide derivatives as cell adhesion modulators TANABE SEIYAKU CO. LTD. (JP) 1998-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180148418-A1 AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES C1R, C9, C1S CHRNB2 4333/4885CHRNA4 4447/4885CHRNA3 4108/4885
US-20090156465-A1 DERIVATIVES OF BETA-AMINO ACID AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS DPP4, DPP3, DPP7 CHRNB2 4255/4885CHRNA4 3383/4885CHRNA3 4178/4885
US-20190352313-A1 1H-PYRROLE-2,5-DIONE COMPOUNDS AND METHODS OF USING THEM TO INDUCE SELF-RENEWAL OF STEM/PROGENITOR SUPPORTING CELLS MCL1, PROX1, MKI67 CHRNB2 2385/4885CHRNA4 4143/4885CHRNA3 4060/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.